DESCRIPTION (provided by applicant): While our current understanding of the pathophysiological mechanisms involved in the development of ethanol (EtOH)-induced liver injury is incomplete, both innate and adaptive immune responses are implicated in initiation and progression of liver injury. The complement (C) system is a network of more than 30 proteins, involved in both innate and adaptive immune responses. Activation of the C pathway can occur via the classical, lectin or alternative pathways, all three pathways culminate in the activation of C3, which in turn activates the terminal pathway leading to the formation of the C5b-9 membrane attack complex (MAC). C is critical to an organism's ability to ward off infection and also plays a role in the repair response to injury, but uncontrolled C activation may itself cause cellular injury. Further, the C pathway contributes to activation of a number of pro-inflammatory responses. We have recently investigated whether C activation is required for chronic EtOH-induced liver injury in wild-type mice and mice lacking the 3rd (C3) or 5th (C5) components of the C activation pathway, as well as mice lacking decay accelerating factor (CD55/DAF) or CD59, intrinsic regulatory proteins in the C pathway. Chronic EtOH feeding to mice increased activation of C3, increasing the concentration of C3a in the plasma. Importantly, C3 -/- and C5 -/- mice were protected from EtOH-induced fatty liver injury. Injury was exacerbated in CD55/DAF -/- mice, while CD59 -/- were protected from EtOH-induced fatty liver injury. Here we propose to test the hypothesis that C activation is critically involved in the development of chronic EtOH-induced fatty liver and that the intrinsic C regulator CD55/DAF acts as a primary brake against the deleterious effects of EtOH in the liver. Further, we hypothesize that activation of the terminal C pathway and formation of the MAC serves to dampen EtOH- induced injury in the liver. We propose four specific aims to investigate the mechanisms by which the C system modulates EtOH-induced liver injury in a mouse model of chronic EtOH exposure, as well as in primary cell cultures. 1) Elucidate the specific C activation pathway(s) involved in activation of C3- dependent damage by EtOH, 2) Determine the specific contributions of C3 versus C5 in mediating chronic EtOH-induced fatty liver injury, 3) Understand the protective function of the terminal C pathway/MAC during chronic EtOH exposure and 4) Determine the effects of chronic EtOH feeding on the response of Kupffer cells and hepatocytes to activation by C3a and C5a. Understanding the mechanisms by which chronic EtOH feeding activates the C system and the role of C in mediating liver injury will facilitate the development of pharmacotherapeutic strategies to prevent and/or reverse EtOH-induced liver injury.
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
135781701
UEI
M5QFLTCTSQN6
Project Start Date
11-September-2006
Project End Date
31-August-2011
Budget Start Date
11-September-2006
Budget End Date
31-August-2007
Project Funding Information for 2006
Total Funding
$347,625
Direct Costs
$225,000
Indirect Costs
$122,625
Year
Funding IC
FY Total Cost by IC
2006
National Institute on Alcohol Abuse and Alcoholism
$347,625
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AA016399-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AA016399-01
Patents
No Patents information available for 1R01AA016399-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AA016399-01
Clinical Studies
No Clinical Studies information available for 1R01AA016399-01
News and More
Related News Releases
No news release information available for 1R01AA016399-01
History
No Historical information available for 1R01AA016399-01
Similar Projects
No Similar Projects information available for 1R01AA016399-01